Allergan signs $750 million settlement with purchasers of Alzheimer's drug Namenda

Purchasers of Allergan Plc's Namenda asked a federal judge on Tuesday to approve a $750 million settlement of claims that the drugmaker conspired to keep generic versions of the Alzheimer's medication off the market.